Kura Oncology's Darlifarnib Combo Shows Strong Tumor Responses in KRAS-Mutated Cancers
Event summary
- Kura Oncology reported 77% tumor shrinkage in KRAS G12C-mutated solid tumors using darlifarnib + adagrasib combo in Phase 1a trial (N=30).
- Objective response rates: 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients.
- Data presented at ASCO Annual Meeting on May 30, 2026; virtual investor event scheduled for June 3, 2026.
- Combination well-tolerated with manageable safety profile; 37% of patients remained on study treatment as of March 25, 2026.
The big picture
Kura Oncology's positive Phase 1a data for darlifarnib + adagrasib highlights the growing focus on combination therapies to overcome resistance in KRAS-mutated cancers. The results reinforce the potential of targeting the mTORC1-RHEB pathway, a key resistance node shared across multiple targeted therapy classes. This approach could expand treatment options for heavily pretreated patients with difficult-to-treat tumor types like PDAC, NSCLC, and CRC.
What we're watching
- Combination Strategy
- Whether darlifarnib can establish itself as a preferred combination partner for KRAS inhibitors and other precision therapies.
- Regulatory Pathway
- The pace at which Kura can advance this combination through later-stage trials and potential regulatory approvals.
- Market Positioning
- How these results position Kura against competitors developing similar resistance-overcoming strategies in KRAS-mutated cancers.
Related topics